Topic: Blood-brain barrier
The CK1 inhibitor passed tests in healthy volunteers at Pfizer before getting derailed by the Big Pharma’s retreat from neuroscience R&D in 2018.
A Cedars-Sinai team used a polymer scaffold to deliver two types of immune checkpoint inhibitors in mouse models of glioblastoma.
ArunA Bio CEO Mark Sirgo and Chief Scientific Officer Steve Stice discuss exosomes and how they can be harnessed to treat CNS diseases.
Nektar Therapeutics created Inheris Biopharma, a new subsidiary that will take over the launch of Nektar’s pain drug, NKTR-181.
Immune molecules from sea lampreys could inspire new treatments for brain tumors, trauma and neurodegenerative diseases.
Paul-Peter Tak joins Kintai Therapeutics as it steers its “precision enteric medicines” toward the clinic, with the first trials slated to start in 2020.
Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.
The partners will work to develop adeno-associated virus vectors capable of crossing the blood-brain barrier.
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
Denali will acquire the rights to bispecific antibodies targeting the blood-brain barrier that were developed under its collaboration with F-star.